WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and dicer substrate RNAi molecules, today announced that James C. Jenson, Ph.D., chief executive officer and co-founder of Dicerna, will be presenting an overview of the Company’s recent progress and upcoming milestones at the following fall investor conferences:
